24th Porto Cancer Meeting 2017
Liquid biopsy: bringing precision medicine closer to oncology
Dr. Quagliata is Senior Director of the Contract R&D Unit at the Institute of Medical Genetics Pathology, care of the University Hospital Basel. Dr. Quagliata is formally trained in Medical Biotechnology with a PhD in Vascular Medicine. Since moving back to Switzerland from the National Institute of Health – NIH (Bethesda, USA), Dr. Quagliata originally established the NGS technology at his current Institution in Basel, where is also leading the Molecular Diagnostics Team. Dr Quagliata’s Team has been among the first in Europe introducing Next Generation Sequencing (NGS) in routine Molecular Diagnostics, and applied it to the analysis of Liquid Biopsy with the ultimate goal of enabling Precision Medicine. Nowadays, theMolecular Diagnostics Team represents the lager hospital-based provider of diagnostic sequencing services in Switzerland with thousands of samples analysed using NGS within the last years, and hundreds of Liquid Biopsies.